Provectus Biopharmaceuticals Inc
OTC:PVCT
Provectus Biopharmaceuticals Inc
OTC:PVCT
Price:
0.047
USD
0.86%
Market Closed
Market Cap:
$19.8m
Relative Value
The Relative Value of one
PVCT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 0.047 USD,
Provectus Biopharmaceuticals Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PVCT Relative Value
HIDDEN
Multiples Across Competitors
PVCT Competitors Multiples
Provectus Biopharmaceuticals Inc Competitors
Provectus Biopharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Provectus Biopharmaceuticals Inc
OTC:PVCT
|
19.8m USD | 42.9 | -3.1 | -3.8 | -3.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
963B USD | 14.8 | 46.7 | 31.4 | 33.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
599.3B USD | 6.4 | 22.4 | 15.5 | 19.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
288.1B CHF | 4.7 | 30.6 | 12.9 | 15.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
250B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP | 5.4 | 31.2 | 17.3 | 24.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.9B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
